Talk:Indacaterol/glycopyrronium bromide

Latest comment: 4 years ago by Spintendo in topic Proposed changes

Proposed changes

edit

Hello, I am a Sunovion employee and would like to help update this Wikipedia entry. There are updates that are needed that I would like to work with you on to ensure it’s updated according to Wikipedia guidelines. I look forward to working with you.

Please add ‘In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugdeliverybusiness.com/sunovion-novartis-ink-licensing-deal-inhaled-copd-drugs/

Also, add ‘In 2017, the FDA approved Lonhala Magnair, a new drug product, to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugs.com/history/lonhala-magnair.html


Thanks for your help Ed at Sunovion (talk) 18:30, 13 December 2019 (UTC)Reply

Reply 13-DEC-2019

edit

   Edit request partially implemented  

  1.  Y The claim regarding the commercial rights was added to the article.
  2.  N The claim regarding Lonhala Magnair was not added to the article.

Regards,  Spintendo  20:25, 13 December 2019 (UTC)Reply

Proposed changes

edit

Hello, I am a Sunovion employee and would like to help update this Wikipedia page with this edit.

Add ‘In 2017, the FDA approved Lonhala Magnair (glycopyrrolate) Inhalation Solution for the treatment of COPD to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://journals.sagepub.com/doi/full/10.1177/1060028018798753


Thanks for your help Ed at Sunovion (talk) 20:59, 13 December 2019 (UTC)Reply

Reply 13-DEC-2019

edit

   Already declined  

  • This proposal was previously declined. The article does not exist for the promotion of new products.

Regards,  Spintendo  22:10, 13 December 2019 (UTC)Reply